key: cord-0948009-jdtt9mor authors: Chong, Yong; Tani, Naoki; Goto, Takeyuki; Yonekawa, Akiko; Ikematsu, Hideyuki; Shimono, Nobuyuki; Tanaka, Yosuke; Akashi, Koichi title: Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents date: 2021-10-20 journal: J Infect DOI: 10.1016/j.jinf.2021.10.011 sha: 362ee579e1066252e97908437b64e3150d89bd82 doc_id: 948009 cord_uid: jdtt9mor nan Dear editor: We have read the article by Lim et al. with great interest. 1 The authors found rapid and robust antibody responses after adenovirus vector-based SARS-CoV-2 vaccination in previously infected individuals. So far, antibody responses induced by SARS-CoV-2 mRNA vaccination have been intensively investigated. 2 No requirement for the second SARS-CoV-2 vaccine has been discussed in previously infected individuals because of sufficient antibody responses elicited by only one dose. 3 However, the details of antibody responses after SARS-CoV-2 mRNA vaccination in nursing home residents have not been fully characterized, although a few studies have been briefly reported. [4] [5] [6] In this study, we evaluated the antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents, with healthcare workers as a control. COVID-19 outbreaks have severely affected nursing home residents. 7 Infection control during the outbreaks in nursing facilities is a critical public health issue. This study was conducted as a serological follow-up evaluation after reporting a COVID-19 outbreak in a nursing facility in April 2020. 8 There was an outbreak in the hospital adjacent to the facility in January 2021. SARS-CoV-2-infected healthcare workers in the hospital were also included in the study control. BNT162b2 mRNA vaccination was performed twice at a 21-day interval from May to July, 2021. Serum samples after the first and second dose were collected on the scheduled day 21. Serological testing was performed using the serum samples collected before and after Figure 2A . In SARS-CoV-2-naive healthcare workers and residents, increasing age significantly correlated with a decrease in IgG levels after both doses. In contrast, in previously infected healthcare workers and residents, a decline in antibody levels with increasing age was not shown. Next, IgG levels in the previously infected individuals were compared between two groups based on the duration from infection to vaccination ( Figure 2B ). Post-vaccination IgG levels in the group with 13 to 15 months after infection appeared to be higher than in the group with 3 to 4 months, regardless of healthcare workers or residents. It was particularly significant in the comparison after the second dose (P = 0.0002). In this study, we showed that after the second dose, anti-spike IgG levels in SARS-CoV-2-naive residents were extremely lower than those in SARS-CoV-2-naive healthcare workers. When using Abbott anti-spike IgG levels of ≥ 4,160 AU/mL as a threshold level indicating highly effective antibody neutralization, our results suggested that approximately 60% of SARS-CoV-2-naive residents after vaccination could not achieve antibody levels required to protect them against infection. SARS-CoV-2-naive nursing home residents may remain much more vulnerable to breakthrough infection than the general adult population. The clinical efficacy of the third (booster) dose of BNT162b2 vaccination in the elderly has just been reported. 9 The requirement of a high application order of re-vaccination may be reasonable in SARS-CoV-2-naive nursing home residents. The dynamics of antibody levels after vaccination in SARS-CoV-2 previously infected nursing home residents was completely different from that of SARS-CoV-2-naive residents. In this study, we showed that in previously infected residents after the first dose, antibody levels comparable to SARS-CoV-2-naive healthcare workers after the second dose were induced. Our findings suggest that even advanced aged nursing home residents only require one vaccine dose within approximately one year of their SARS-CoV-2 infection. The study on the third vaccination in the elderly did not include individuals previously infected with SARS-CoV-2. 9 It is likely that there is currently little discussion on the necessity of the third dose for previously infected individuals, including nursing home residents. There has been little information on the factors related to rapidly increasing antibody responses after the vaccination of SARS-CoV-2 previously infected nursing home residents. It would be evident in this study that aging is not associated with an increase in post-vaccination antibody levels in SARS-CoV-2 previously infected individuals, at least within 15 months after infection. We obtained a finding that post-vaccination antibody levels were significantly higher in individuals with the longer duration after infection. Antibody responses after SARS-CoV-2 vaccination were more pronounced in adults with >3 months after infection than in those with 1-2 months. 10 Intriguingly, SARS-CoV-2-specific memory function to demonstrate booster responses after vaccination might be maintained more effectively in individuals with the period of one year after infection than in those with three months, even in advanced aged nursing home residents. Abbott anti-spike IgG levels of ≥ 4,160 AU/mL, which were used as a threshold of highly efficient antibody neutralization, could not necessarily reflect the standard levels In conclusion, SARS-CoV-2-naive nursing home residents may not achieve sufficient antibody responses against SARS-CoV-2 infection, despite complete vaccination. In contrast, previously infected residents could maintain rapid and robust antibody responses to vaccination even more than one year after infection. We believe that our serological data of nursing home residents could be of significant use to many healthcare professionals for future control measures for COVID-19 outbreaks. Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without Is a single COVID-19 vaccine dose enough in convalescents? Covid-19: People who have had infection might only need one dose of mRNA vaccine Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose Humoral and cellular immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel Antibody Response in Persons with Past Natural Infection First, we would like to thank Atsushi Hisaeda and Seiji Sasaki for their technical support. Next, we sincerely thank Junko Nakahara for all of her support in the investigation. We would also like to thank the entire Department of Clinical Chemistry (Kanenokuma Hospital), including Tomoyuki Fukamachi. Finally, we thank all staff members of the facility for their dedicated work. There are no competing interests to declare for any of the authors. No external funding was received for this study.